163 related articles for article (PubMed ID: 38216214)
21. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients.
Dutta S; Shah R; Singhal S; Singh S; Piparva K; Katoch CDS
Expert Opin Drug Saf; 2024 Feb; 23(2):187-198. PubMed ID: 38063346
[TBL] [Abstract][Full Text] [Related]
22. Inclisiran and cardiovascular events: a comprehensive review of efficacy, safety, and future perspectives.
Mohamed AA; Ray KK
Curr Opin Cardiol; 2023 Nov; 38(6):527-532. PubMed ID: 37522763
[TBL] [Abstract][Full Text] [Related]
23. First clinical experiences with inclisiran in a real-world setting.
Mulder JWCM; Galema-Boers AMH; Roeters van Lennep JE
J Clin Lipidol; 2023; 17(6):818-827. PubMed ID: 37775462
[TBL] [Abstract][Full Text] [Related]
24. Inclisiran: How Widely and When Should We Use It?
Pirillo A; Catapano AL
Curr Atheroscler Rep; 2022 Oct; 24(10):803-811. PubMed ID: 35877035
[TBL] [Abstract][Full Text] [Related]
25. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Raal FJ; Kallend D; Ray KK; Turner T; Koenig W; Wright RS; Wijngaard PLJ; Curcio D; Jaros MJ; Leiter LA; Kastelein JJP;
N Engl J Med; 2020 Apr; 382(16):1520-1530. PubMed ID: 32197277
[TBL] [Abstract][Full Text] [Related]
26. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
Warden BA; Duell PB
J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
[TBL] [Abstract][Full Text] [Related]
27. Current and future options in cholesterol lowering treatments.
Elis A
Eur J Intern Med; 2023 Jun; 112():1-5. PubMed ID: 36813611
[TBL] [Abstract][Full Text] [Related]
28. PCSK9-lowering RNAi contender clears first phase III trial.
Mullard A
Nat Rev Drug Discov; 2019 Sep; 18(10):737. PubMed ID: 31570849
[No Abstract] [Full Text] [Related]
29. Do PCSK9 inhibitors do anything more than reduce LDL cholesterol?
Bamji AN
BMJ; 2020 Mar; 368():m1159. PubMed ID: 32209543
[No Abstract] [Full Text] [Related]
30. The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions.
Lehoux D; Kallend D; Wijngaard PLJ; Brown AP; Zerler B
Pharmacol Res Perspect; 2023 Apr; 11(2):e01080. PubMed ID: 37021909
[TBL] [Abstract][Full Text] [Related]
31. [Long-lasting LDL-C lowering: silence at last].
Achard M; Buhayer A; Dobretz K; Ehret G; Mach F
Rev Med Suisse; 2021 May; 17(740):1039-1046. PubMed ID: 34042340
[TBL] [Abstract][Full Text] [Related]
32. Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials.
Landmesser U; Koenig W; Leiter LA; Raal FJ; Ray KK; Wright RS; Han J; Conde LG; Schwartz GG
Atherosclerosis; 2023 Dec; 386():117354. PubMed ID: 38016401
[TBL] [Abstract][Full Text] [Related]
33. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies.
Brandts J; Ray KK
Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819
[TBL] [Abstract][Full Text] [Related]
34. High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany.
Makhmudova U; Schatz U; Perakakis N; Kassner U; Schumann F; Axthelm C; Stürzebecher P; Sinning DL; Doevelaar A; Rohn B; Westhoff T; Vogt A; Scholl M; Kästner U; Geiling JA; Stach K; Mensch J; Lorenz E; Paitazoglou C; Eitel I; Baessler A; Steinhagen-Thiessen E; Koenig W; Schulze PC; Landmesser U; Laufs U; Weingärtner O;
Clin Res Cardiol; 2023 Nov; 112(11):1639-1649. PubMed ID: 37422840
[TBL] [Abstract][Full Text] [Related]
35. Inclisiran, the billion-dollar drug, to lower LDL cholesterol - is it worth it?
Doggrell SA
Expert Opin Pharmacother; 2020 Nov; 21(16):1971-1974. PubMed ID: 32749892
[TBL] [Abstract][Full Text] [Related]
36. Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic.
Chiou TT; Tomasi K; Taub PR; Wilkinson MJ
J Clin Lipidol; 2023; 17(1):73-77. PubMed ID: 36371372
[TBL] [Abstract][Full Text] [Related]
37. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review.
Merćep I; Friščić N; Strikić D; Reiner Ž
Cardiovasc Ther; 2022; 2022():8129513. PubMed ID: 35237348
[TBL] [Abstract][Full Text] [Related]
38. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
39. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
Landmesser U; Haghikia A; Leiter LA; Wright RS; Kallend D; Wijngaard P; Stoekenbroek R; Kastelein JJ; Ray KK
Cardiovasc Res; 2021 Jan; 117(1):284-291. PubMed ID: 32243492
[TBL] [Abstract][Full Text] [Related]
40. PCSK9-gene-silencing, cholesterol-lowering drug impresses.
Sheridan C
Nat Biotechnol; 2019 Dec; 37(12):1385-1387. PubMed ID: 31796927
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
